MALARIA ELIMINATION THROUGH ASYMPTOMATIC DIAGNOSIS CAMPAIGNS
THE CASE FOR MALARIA ERADICATION
Damaged Public Health
Malaria is an infectious disease of the most vulnerable that affected
229 million people
were children under the age of five
Malaria is among
the reasons for
lost economic growth
, particularly for low-income countries.
THE CASE FOR ASYMPTOMATIC DIAGNOSIS
current malaria diagnostic
technologies on the market
Malaria Rapid Diagnostic Tests (mRDTs)
are not designed to detect asymptomatic carriers.
global agendas on malaria eradication cannot yet underline the need for asymptomatic screening
due to the current lack of an available tool.
HOW OUR CAMPAIGN WORKS
INCENTIVIZE & EDUCATE
USING OUR DIAGNOSTIC TOOLKIT
TREATMENT & DATA COLLECTION
Raise awareness of the importance of malaria asymptomatic screening and improve general health literacy within the local community in regard to malaria elimination through our collaboration with local health organizations.
Technical training for local health practitioners on the use of our novel malaria diagnostic toolkit.
All asymptomatic diagnoses will be done using Hemolytics' malaria diagnostic toolkit with a dual approach: active case detection (ACD) and reactive case detection (RACD).
Detected asymptomatic carriers of the malaria parasites will be treated accordingly.
Data will be collected to evaluate the impact of asymptomatic screening in eliminating malaria.
Hemolytics is a deep-tech impact start-up based in the bilingual city of Fribourg, Switzerland. Originally a research project at the Adolphe Merkle Institute at the University of Fribourg, Hemolytics has grown into a spin-off with a pre-founding team that is currently planning for Hemolytics' foundation at the end of summer 2021. The company's mission is to bring Hemolytics' life-saving asymptomatic diagnostic campaigns and technology to as many underserved communities as possible.
We aim to demonstrate the importance of asymptomatic screening in the arsenal of tools to fight malaria, which will put it on WHO’s official global agenda for malaria eradication. This will pave ways for us as well as other innovators that share the mutual goal of removing this ancient disease from our world once and for all.
We are a multidisciplinary team of five changemakers who are inspired to create a lasting social impact through knowledge-based innovation and entrepreneurship (click on the images for more details).
Behind the pre-founding team is our board of advisors, who have been guiding us with their scientific insight, industry experience, and more importantly, a strong belief in Hemolytics (click on the images for more details).
OUR MILESTONES (HIGHLIGHTS)
19th May: Patent application
Seed round funding
September: Incorporate Hemolytics SA